| 
							
      					 | 
  					 
  					
    					 | 
   					 
   										
    					| Nedaplatin Combined Gemcitabine Treatment of Advanced Non-small Cell Lung Cancer and Adverse Reactions | 
  					 
  					  															
						| The Second People’s Hospital of Zhenjiang, Zhenjiang 212000, China | 
					 
										
						 | 
					 
				 
				
				
					
						
							
								
									
										
											
                        					 
												
													
													    | 
													    	
														 | 
													 
																										
													
														
															
													
													    | 
													     		                            						                            																	    Abstract  Objective:To analyze the treatment of advanced non-small cell lung cancer and the adverse reactions by combining nedaplatin with gemcitabine.Method:28 patients from 2013.6 to 2014.7 were chosen as research object,which had been diagnosed as non-small cell lung cancer through the cell and pathology morphology, and they all used intravenous nedaplatin 80 mg/m2 on the 1 st day, gemcitabine( Gem) 800 mg/m2 IV, on the day 1, 8, 21.Repeat the treatment, evaluated the effective after two cycles.At the same time Tropisetron 5 mg intravenous injection was given to prevent vomiting.Result:The clinical evaluation of patients were CR 2 cases, PR 10 cases, NC 8 cases, PD 8 cases, RR( PR+CR)( 12/28) 42.9%, the adverse reaction was nausea and vomiting, there was no Ⅲ-Ⅳ degree of nausea and vomiting, and 25 cases were Ⅰ-Ⅲ mild bone marrow suppression, 4 cases were Ⅲ myelosuppression, no Ⅳmyelosuppression.Conclusion:The treatment of advanced lung cancer by combining nedaplatin with gemcitabine has better exact effect, and toxicity can be controlled, so it is worthy of clinical development.
																										     | 
														 
														
														
															| 
															    															    															    															 | 
														 
														 																											    																														 
															 | 
															
																
															 | 
													    	
															 | 
																
															
														 
														
													 
													
												 
												
												
												
											
											 
											
											 
										 
									 | 
								 
							 
						 | 
					 
				 
			
		 |